Relevance of pre-analytical blood management on the emerging cardiovascular protein biomarkers TWEAK and HMGB1 and on miRNA serum and plasma profiling

• Verfasst von: Basso, Daniela [VerfasserIn]
• Verfasst von: Weis, Tanja [VerfasserIn]
• Verfasst von: Katus, Hugo [VerfasserIn]
• Titel: Relevance of pre-analytical blood management on the emerging cardiovascular protein biomarkers TWEAK and HMGB1 and on miRNA serum and plasma profiling
• Verf.angabe: Daniela Basso, Andrea Padoan, Thomas Laufer, Vittorio Aneloni, Stefania Moz, Hannah Schroers, Michela Pelloso, Anna Saiz, Medea Krapp, Paola Fogar, Paola Cornoldi, Carlo-Federico Zambon, Elisa Rossi, Marco La Malfa, Alberto Marotti, Thomas Brefort, Tanja M. Weis, Hugo A. Katus, Mario Plebani
• Jahr des Originals: 2016
• Umfang: 8 S.
• Fussnoten: Available online 12 November 2016 ; Gesehen am 10.09.2018
• Titel Quelle: Enthalten in: Clinical biochemistry
• Jahr Quelle: 2017
• Band/Heft Quelle: 50(2017), 4, S. 186-193
• ISSN Quelle: 1873-2933
• DOI: doi:10.1016/j.clinbiochem.2016.11.005
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1580801668

Abstract

Background: Disease-independent sources of biomarker variability include pre-analytical, analytical and biological variance. The aim of the present study was to evaluate whether the pre-analytical phase has any impact on the emerging heart disease TWEAK and HMGB1 protein markers and miRNA biomarkers, and whether peptidome profiling allows the identification of pre-analytical quality markers. Methods: An assessment was made of sample type (serum, EDTA-Plasma, Citrate-Plasma, ACD-plasma, Heparin-plasma), temperature of sample storage (room temperature or refrigerated), time of sample storage (0.5, 3, 6 and 9h) and centrifugation (one or two-step). Aliquots of all processed samples were immediately frozen (−80°C) before analysis. Proteins were assayed by ELISAs, miRNA expression profile by microarray and peptidome profiling by MALDI-TOF/MS. Results: Temperature, time and centrifugation had no impact on TWEAK and HMGB1 results, which were significantly influenced by matrix type, TWEAK levels being significantly higher (F=194.7, p<0.0001), and HMGB1 levels significantly lower (F=36.32, p<0.0001) in serum than in any other plasma type. Unsuitable miRNA results were obtained using Heparin-plasma. Serum miRNA expression profiles depended mainly on temperature, while EDTA-plasma miRNA expression profiles were strongly affected by the centrifugation method used. MALDI-TOF/MS allowed the identification of seven features as indices of pre-analytical serum (m/z at 1206, 1350, 1865 and 2021) or EDTA-plasma (m/z 1897, 2740 and 2917) degradation. Conclusions: Serum and EDTA-plasma allow the analysis of both proteins and miRNA emerging biomarkers of heart diseases. Refrigerated storage prevents an altered miRNA expression profile also in cases of a prolonged time-interval between blood drawing and processing.